Select a community
All Communities
Home > Community Treatment Reports > Enablex (darifenacin) Treatment Report
What is Enablex?

Enablex is a brand name for the drug darifenacin. It is an extended release preparation that is used for the management of symptoms of bladder overactivity (urge incontinence, urgency, and frequency).

Side Effects

Side effects as an overall problem

Severe
1 25%
Moderate
0 0%
Mild
3 75%
None
0 0%

Most commonly reported side effects

slows down starting urination
2 50%
Dry mouth (xerostomia)
2 50%
Constipation
1 25%
throat tightening
1 25%
vocalcord paralysis
1 25%
paralysis of legs
1 25%
  • Mild
  • Moderate
  • Severe

Dosages

  15mg as needed daily 7.2 mg daily 7.5 daily 7.5 mg daily 15 mg daily 25 mg daily 30 mg daily
  1 Number of Patients: 1 3 Number of Patients: 3 1 Number of Patients: 1 1 Number of Patients: 1 24 Number of Patients: 24 24 Number of Patients: 24 1 Number of Patients: 1 1 Number of Patients: 1  

Stop Reasons

Why Patients Stopped Taking Enablex (multiple reasons could be selected)
Reason # Patients Percentage of patients
Did not seem to work
5 45% Did not seem to work: 45%
Expense
3 27% Expense: 27%
Personal research
2 18% Personal research: 18%
Doctor's advice
1 9% Doctor's advice: 9%
Side effects too severe
1 9% Side effects too severe: 9%
Not indicated
1 9% Not indicated: 9%

See all 11 patients who’ve stopped taking Enablex

Currently Taking Enablex

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
1
2
2
5
11
11

Stopped Taking Enablex

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
1
1
3
4
0
2

Adherence, Burden & Cost See details from patient evaluations

Adherence

Taking treatment as prescribed

Always
4 100%
Usually
0 0%
Sometimes
0 0%
Never
0 0%

Burden

Difficulty being on treatment

Very
1 25%
Somewhat
0 0%
A little
0 0%
Not at all
3 75%

Cost

Paid out of pocket

$200+
0 0%
$100-199
0 0%
$50-99
0 0%
$25-49
3 75%
< $25
1 25%

See more information, including instructions, precautions, side effects, and interactions.

Report created on November 22, 2009.